The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise, entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.
Avelios Medical operates a modular clinic platform designed to enhance patient care by digitizing and optimizing clinic processes. The platform offers user-friendly software that supports healthcare staff in their daily operations while facilitating the integration of innovative technologies such as artificial intelligence, big data, telemedicine, patient applications, and wearables. By streamlining workflows and automating various tasks, Avelios Medical aims to significantly improve both patient outcomes and healthcare research, making it a valuable resource for hospitals and clinics seeking to modernize their services.
Laclarée
Seed Round in 2025
Laclarée Vision specializes in the development of adaptive eyeglasses designed to correct presbyopia. Founded in 2016 and based in Lyon, France, the company utilizes patented fluid technology to create lenses that automatically adjust in real-time to various viewing distances. This innovative approach addresses the needs of individuals aged 45 and older who often find traditional solutions, such as progressive lenses or multiple pairs of glasses, unsatisfactory. By combining adaptive lens technology with refractive correction for conditions like astigmatism, myopia, and hyperopia, Laclarée aims to provide a clearer vision experience for its users.
Lindis Blood Care
Venture Round in 2024
Lindis Blood Care´s mission is to optimise the outcome of cancer surgeries by developing a Medical Device to remove cancer cells from blood during cancer surgeries to enable Autologous Blood Transfusion.
Sedivention
Pre Seed Round in 2024
Sedivention is a medical technology startup that enables a one-time, interventional, and minimally invasive therapy for obesity. The company is developing a cryo catheter that ablates the gastric branches of the vagus nerve within minutes. As a one-time, minimally invasive procedure, the procedure can be performed in an outpatient setting, similar to a gastroscopy.
Lymphatica Medtech
Series B in 2024
Lymphatica Medtech SA is a Swiss company focused on designing and manufacturing medical devices for the treatment of lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed LymphoDrain, an innovative medical device that aims to re-establish lymphatic circulation. This system includes an active implantable lymphatic bypass, featuring a magnetically controlled micropump and subcutaneous catheters that facilitate the internal drainage of lymphatic fluid from multiple points within the affected limb. Lymphatica Medtech also produces essential components for LymphoDrain, such as the micropump head and wearable controller, providing a minimally invasive solution for individuals suffering from persistent lymphedema.
CustomSurg
Seed Round in 2024
Bone fractures involving a joint are complex in nature, resulting in difficult and time-consuming procedures for the treating orthopaedic surgeon. We provide fracture specific optimization of complex bone reconstruction. Our software solution ensures efficacy of personalized surgical planning, as well as “save and effective” patient-specific implant and instrument design, changing the treatment strategy from a subjective to an objective approach with more predictable outcomes. This could improve outcomes of 400,000 trauma patients, addressing a $1.2 B market. A Harvard Medical School surgeon directing the medical aspects, provides crucial credibility.
Altavo
Series A in 2024
Altavo is a medical device startup focused on creating artificial voice solutions for individuals who have lost their ability to speak due to surgery or disease. By leveraging advanced machine learning and cutting-edge sensor technology, Altavo develops custom, natural-sounding voices that enable voiceless individuals to communicate effectively. The company's innovative approach combines speech recognition and synthesis, significantly enhancing the quality of life for those with speech disorders.
Kranus Health
Series A in 2023
Kranus Health is a prominent global provider of virtual care in the field of Urology, specializing in clinically validated therapies for various conditions, including those related to Andrology and Uro-Oncology. The company operates a digital health platform designed to assist men in overcoming issues such as erectile dysfunction and nausea. Through this platform, Kranus Health offers a comprehensive range of services, including pelvic floor training, cardiovascular training, mental health support, medical supervision, and preventive therapies. This approach empowers patients to manage their health conditions from the comfort of their homes, promoting healthier and longer lives.
Kranus Health
Series A in 2022
Kranus Health is a prominent global provider of virtual care in the field of Urology, specializing in clinically validated therapies for various conditions, including those related to Andrology and Uro-Oncology. The company operates a digital health platform designed to assist men in overcoming issues such as erectile dysfunction and nausea. Through this platform, Kranus Health offers a comprehensive range of services, including pelvic floor training, cardiovascular training, mental health support, medical supervision, and preventive therapies. This approach empowers patients to manage their health conditions from the comfort of their homes, promoting healthier and longer lives.
Altavo
Seed Round in 2022
Altavo is a medical device startup focused on creating artificial voice solutions for individuals who have lost their ability to speak due to surgery or disease. By leveraging advanced machine learning and cutting-edge sensor technology, Altavo develops custom, natural-sounding voices that enable voiceless individuals to communicate effectively. The company's innovative approach combines speech recognition and synthesis, significantly enhancing the quality of life for those with speech disorders.
Avelios Medical
Seed Round in 2021
Avelios Medical operates a modular clinic platform designed to enhance patient care by digitizing and optimizing clinic processes. The platform offers user-friendly software that supports healthcare staff in their daily operations while facilitating the integration of innovative technologies such as artificial intelligence, big data, telemedicine, patient applications, and wearables. By streamlining workflows and automating various tasks, Avelios Medical aims to significantly improve both patient outcomes and healthcare research, making it a valuable resource for hospitals and clinics seeking to modernize their services.
Reactive Robotics
Venture Round in 2021
Reactive Robotics GmbH, founded in April 2015 and based in Gilching, Germany, specializes in the design, manufacture, and sale of rehabilitation robots aimed at early movement rehabilitation following neurological injuries and orthopedic surgeries. The company focuses on gait rehabilitation for neurological patients and assists orthopedic patients recovering from joint replacements. With a team that has over 12 years of experience in rehabilitation robotics, Reactive Robotics benefits from a robust clinical network and a group of advisors who provide guidance on engineering, legal matters, and medical device registration. Additionally, the company develops AI-driven robotic systems that support very early mobilization therapy, facilitating faster recovery for patients in intensive care units while alleviating the workload of nursing staff.
Kranus Health
Seed Round in 2021
Kranus Health is a prominent global provider of virtual care in the field of Urology, specializing in clinically validated therapies for various conditions, including those related to Andrology and Uro-Oncology. The company operates a digital health platform designed to assist men in overcoming issues such as erectile dysfunction and nausea. Through this platform, Kranus Health offers a comprehensive range of services, including pelvic floor training, cardiovascular training, mental health support, medical supervision, and preventive therapies. This approach empowers patients to manage their health conditions from the comfort of their homes, promoting healthier and longer lives.
Lymphatica Medtech
Series A in 2020
Lymphatica Medtech SA is a Swiss company focused on designing and manufacturing medical devices for the treatment of lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed LymphoDrain, an innovative medical device that aims to re-establish lymphatic circulation. This system includes an active implantable lymphatic bypass, featuring a magnetically controlled micropump and subcutaneous catheters that facilitate the internal drainage of lymphatic fluid from multiple points within the affected limb. Lymphatica Medtech also produces essential components for LymphoDrain, such as the micropump head and wearable controller, providing a minimally invasive solution for individuals suffering from persistent lymphedema.
Kumovis
Series A in 2020
Kumovis is a medical technology company focused on advancing the field of 3D printing for industrial and medical applications. It has developed a specialized 3D printing system that integrates clean room technology, allowing for the precise processing of high-performance polymers. This innovation enables the creation of patient-customized implants, facilitating more convenient and effective medical operations in hospitals. Through its cutting-edge technology, Kumovis aims to enhance the capabilities of medical professionals and improve patient outcomes.
Biograil
Seed Round in 2020
Biograil, founded in 2019 and led by CEO Karsten Lindhardt, specializes in developing a medical device that innovatively replaces traditional injection systems for administering medications. Utilizing an injection molding technique, the device is encapsulated in a standard-sized capsule and employs the body's natural peristaltic forces to deliver biologics directly into the gastrointestinal wall. This approach eliminates the need for mechanical moving components, allowing for a painless and efficient method of drug delivery to patients.
Lindis Blood Care
Venture Round in 2019
Lindis Blood Care´s mission is to optimise the outcome of cancer surgeries by developing a Medical Device to remove cancer cells from blood during cancer surgeries to enable Autologous Blood Transfusion.
Laclarée
Seed Round in 2019
Laclarée Vision specializes in the development of adaptive eyeglasses designed to correct presbyopia. Founded in 2016 and based in Lyon, France, the company utilizes patented fluid technology to create lenses that automatically adjust in real-time to various viewing distances. This innovative approach addresses the needs of individuals aged 45 and older who often find traditional solutions, such as progressive lenses or multiple pairs of glasses, unsatisfactory. By combining adaptive lens technology with refractive correction for conditions like astigmatism, myopia, and hyperopia, Laclarée aims to provide a clearer vision experience for its users.
Kumovis
Seed Round in 2018
Kumovis is a medical technology company focused on advancing the field of 3D printing for industrial and medical applications. It has developed a specialized 3D printing system that integrates clean room technology, allowing for the precise processing of high-performance polymers. This innovation enables the creation of patient-customized implants, facilitating more convenient and effective medical operations in hospitals. Through its cutting-edge technology, Kumovis aims to enhance the capabilities of medical professionals and improve patient outcomes.
Reactive Robotics
Series B in 2017
Reactive Robotics GmbH, founded in April 2015 and based in Gilching, Germany, specializes in the design, manufacture, and sale of rehabilitation robots aimed at early movement rehabilitation following neurological injuries and orthopedic surgeries. The company focuses on gait rehabilitation for neurological patients and assists orthopedic patients recovering from joint replacements. With a team that has over 12 years of experience in rehabilitation robotics, Reactive Robotics benefits from a robust clinical network and a group of advisors who provide guidance on engineering, legal matters, and medical device registration. Additionally, the company develops AI-driven robotic systems that support very early mobilization therapy, facilitating faster recovery for patients in intensive care units while alleviating the workload of nursing staff.
CryoTherapeutics
Series B in 2016
CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in developing a proprietary cryotherapy system aimed at treating coronary artery disease, which is a leading cause of heart attacks. The company focuses on demonstrating clinical benefits and advancing early-stage commercialization of its innovative catheter system that employs cryoenergy to address issues related to diseased coronary arteries. By proving the safety and efficacy of cryoenergy in the cardiovascular context, CryoTherapeutics aims to provide heart surgeons with an effective tool to prevent heart attacks and enhance patient outcomes.
Reactive Robotics
Series A in 2016
Reactive Robotics GmbH, founded in April 2015 and based in Gilching, Germany, specializes in the design, manufacture, and sale of rehabilitation robots aimed at early movement rehabilitation following neurological injuries and orthopedic surgeries. The company focuses on gait rehabilitation for neurological patients and assists orthopedic patients recovering from joint replacements. With a team that has over 12 years of experience in rehabilitation robotics, Reactive Robotics benefits from a robust clinical network and a group of advisors who provide guidance on engineering, legal matters, and medical device registration. Additionally, the company develops AI-driven robotic systems that support very early mobilization therapy, facilitating faster recovery for patients in intensive care units while alleviating the workload of nursing staff.
Cevotec
Seed Round in 2016
Cevotec GmbH, founded in 2015 and based in Munich, Germany, specializes in the design and automation of carbon fiber composites and reinforcements for various industries, including aerospace, medical devices, and sports. The company utilizes its Fiber Patch Placement technology to provide manufacturers with advanced solutions for high-volume production of complex composites. Cevotec's SAMBA systems enable fully automated fiber layup, which significantly enhances production efficiency and quality by allowing the creation of intricate 3D geometries and multi-material laminates. Their technology-specific CAD-CAM software, ARTIST STUDIO, facilitates the generation of patch-based fiber laminates and automates robot programming. By transitioning from manual layup to Cevotec's systems, clients can achieve substantial cost and time savings ranging from 20% to 60%. Additionally, Cevotec offers a comprehensive service portfolio that includes customizations tailored to specific applications and development support based on finite element analysis.
Multiphoton Optics
Series A in 2015
Multiphoton Optics develops and markets 3D printing equipment and software solutions. Its equipment and solutions are used to create products in the fields of photonics, biomedicine, life sciences, and functional materials. Multiphoton Optics offers LithoProf3D, a 3D printing equipment platform, and LithoStream3D and LithoSoft3D, software solutions. The company also provides its customers with prototyping and engineering services, and support for its products. Multiphoton Optics was founded by Ruth Houbertz and Markus Riester in September 2013. It is based in Wurzburg, Germany.
Eyetronic Therapie
Venture Round in 2015
EBS Technologies is a medical device company that has developed a stimulation system for the treatment of neurologically caused impairments such as visual field loss. Such impairments can be the result of stroke, traumatic-brain-injury, glaucoma or several other diseases. The EBS Therapy (previously: NEXT WAVE™Therapy) is a non-invasive optic nerve stimulation deploying weak electrical currents, resulting in neuroregeneration and neuroprotection. Low-voltage electrical pulses are administered at frequencies and amplitudes identified as optimal for each patient, allowing retinal ganglion cells to regenerate and branch out new axons. The company benefits from more than 15 years of research and clinical experience with more than 1,200 patients. Double blind, randomized studies, as well as clinical observations show that the EBS Therapy can partially restore vision field in patients. In 2013 EBS Technologies received the CE Mark for the stimulation device and started the commercial treatment in 2014. There are currently 8 EBS Treatment centers across Germany and the company is slowly widening the network.
Sonormed GmbH
Series A in 2015
Sonormed GmbH is a medical technology company focusing on digital audiology.
Oncgnostics
Series A in 2015
Oncgnostics GmbH, founded in 2012 and based in Jena, Germany, specializes in developing molecular assays that leverage epigenetic biomarkers for early and reliable cancer diagnostics. The company focuses on in vitro diagnostic (IVD) tests that aid in screening, therapeutic decision-making, and follow-up care in cancer treatment. Notably, Oncgnostics has developed GynTect, a diagnostic tool that facilitates the swift and accurate detection of cervical cancer and its precancerous stages. The tests are based on identifying specific DNA regions that are methylated in cancerous and precancerous cells, utilizing established PCR-based technologies suitable for routine molecular diagnostic laboratories. Through its innovative approach, Oncgnostics aims to enhance cancer diagnosis and improve patient outcomes.
Preventicus
Seed Round in 2014
Preventicus GmbH, founded in 2014 and headquartered in Jena, Germany, develops innovative health solutions that utilize smartphone and smartwatch technologies to monitor vital parameters. The company's main product, Preventicus Heartbeats, is a class I medical device designed to identify atrial fibrillation, a condition that increases the risk of stroke. This smart screening solution allows users to check their heart rhythm quickly and conveniently, requiring no additional accessories. The software applications are certified medical devices and have demonstrated a level of accuracy previously achievable only by physicians, making them valuable for private users, corporate clients in occupational health management, and OEM customers. Preventicus focuses on early preclinical risk screening for lifestyle-related illnesses, including heart attacks and strokes, effectively enhancing personal health management.
Medineering
Seed Round in 2014
Medineering is a medical technology company based in Munich, Germany, specializing in innovative robotic systems for minimally invasive head surgery. Founded in 2014, the company develops, patents, and sells a modular range of surgical manipulators that enable clinics and surgeons to customize the level of automation and functionality based on their specific surgical needs and budget constraints. Its product portfolio includes an intelligent positioning arm and compact, application-specific robots designed to assist surgeons in navigating complex anatomical regions. Medineering aims to enhance the potential of minimally invasive surgery through advanced robotic solutions that optimize surgical access and improve working conditions in the operating room.
Scopis
Series A in 2013
Scopis is a developer and manufacturer of clinical navigation system for image guided surgery specializing in laser-based measuring and endoscopic augmented reality. Scopis was founded in August 2010 as a joint spin-off of Charité University Clinic Berlin and Fraunhofer IPK. It received an immediate seed round from German incubator High Tech Gründerfonds (HTGF). The MATRIX POLAR navigation system range was brought on the European market in January 2011. Scopis has since focused on improving the utility of navigation for endoscopic procedures. Notably, the Augmented Reality navigation product MATRIX POLAR AR was launched in August 2011.
Synoste
Venture Round in 2013
Synoste Oy, founded in 2007 and based in Espoo, Finland, specializes in developing innovative solutions for the treatment of skeletal deformities. The company focuses on patient-friendly technologies for various conditions, including congenital limb discrepancies, trauma-related injuries, and craniomaxillofacial deformities. Its flagship product is a third-generation limb-lengthening system that incorporates smart materials, designed to enhance patient comfort during the often-complicated lengthening procedure. This advanced device aims to reduce complications and facilitate quicker recovery, making it a significant improvement over traditional methods. As a subsidiary of Globus Medical, Inc., Synoste continues to advance its mission of providing effective and less painful treatment options for individuals with skeletal deformities.
dentaZOOM
Seed Round in 2013
dentaZOOM specializes in the development and distribution of compact surgical microscopes tailored for dental surgery. The company's products are designed to be small, lightweight, and monocular, featuring an integrated LED light system. This innovative design allows dental professionals to incorporate the microscopes seamlessly into their treatment processes, enhancing visibility and precision during procedures. By prioritizing convenience and functionality, dentaZOOM aims to improve the overall efficiency of dental care.
Photonics Healthcare
Venture Round in 2013
Photonics Healthcare GmbH is a medical device company based in Garching, Germany, specializing in the development and commercialization of clinical monitors for measuring cellular oxygen levels. Its primary product, the COMET Monitor, enables healthcare professionals to non-invasively assess cellular oxygen metabolism, including both availability and consumption, at the bedside. This technology is crucial for detecting hypoxia in tissue cells, allowing doctors to evaluate tissue vitality and make informed decisions regarding treatment interventions. By providing real-time data on cellular oxygen dynamics, Photonics Healthcare supports the timely prevention of organ failure and aims to enhance patient care. Additionally, the company offers contract research programs to further advance its medical technologies.
Eyetronic Therapie
Series B in 2013
EBS Technologies is a medical device company that has developed a stimulation system for the treatment of neurologically caused impairments such as visual field loss. Such impairments can be the result of stroke, traumatic-brain-injury, glaucoma or several other diseases. The EBS Therapy (previously: NEXT WAVE™Therapy) is a non-invasive optic nerve stimulation deploying weak electrical currents, resulting in neuroregeneration and neuroprotection. Low-voltage electrical pulses are administered at frequencies and amplitudes identified as optimal for each patient, allowing retinal ganglion cells to regenerate and branch out new axons. The company benefits from more than 15 years of research and clinical experience with more than 1,200 patients. Double blind, randomized studies, as well as clinical observations show that the EBS Therapy can partially restore vision field in patients. In 2013 EBS Technologies received the CE Mark for the stimulation device and started the commercial treatment in 2014. There are currently 8 EBS Treatment centers across Germany and the company is slowly widening the network.
Dolosys
Venture Round in 2013
Dolosys GmbH is a medical device company focused on the development and production of equipment for the objective measurement of pain and analgesia.
Drug Response Dx
Series A in 2013
Drug Response Dx, headquartered in Hennigsdorf, Germany, was founded in February 2012 by a team of experts including Dr. Zoltán Konthur, Dr. Jörg-M. Hollidt, Dr. Karl Skriner, and Dr. Joachim Rautter. The company specializes in developing biomarker tests specifically designed to evaluate treatment outcomes for rheumatoid arthritis. Their tests utilize a protein that predicts the individual effectiveness of TNF-alpha inhibitors, allowing for personalized treatment planning prior to medication administration. This approach facilitates timely initiation of treatment and increases the likelihood of positive patient outcomes. The company's biomarker set is prevalidated, and they have established proof of concept using serum samples from rheumatoid arthritis patients.
InnoCyte
Series A in 2012
InnoCyte - Technologies for automated Cell Culture. They have the strong belief that automated cell culture could be of inestimable value for cell processing in labs all over the world. InnoCyte brings automated cell culture to the masses - within a benchtop designed, reliable and affordable device.
Oncgnostics
Seed Round in 2012
Oncgnostics GmbH, founded in 2012 and based in Jena, Germany, specializes in developing molecular assays that leverage epigenetic biomarkers for early and reliable cancer diagnostics. The company focuses on in vitro diagnostic (IVD) tests that aid in screening, therapeutic decision-making, and follow-up care in cancer treatment. Notably, Oncgnostics has developed GynTect, a diagnostic tool that facilitates the swift and accurate detection of cervical cancer and its precancerous stages. The tests are based on identifying specific DNA regions that are methylated in cancerous and precancerous cells, utilizing established PCR-based technologies suitable for routine molecular diagnostic laboratories. Through its innovative approach, Oncgnostics aims to enhance cancer diagnosis and improve patient outcomes.
Seiratherm
Venture Round in 2012
Seiratherm is a privately held medical technology company located in Herzogenaurach, Germany, specializing in fluid and body-temperature management devices. The company's innovative devices are designed to quickly and safely regulate the core body temperature of critically ill or surgical patients, targeting pre-set treatment goals. By effectively managing body temperature, Seiratherm's devices help lower metabolic rates, which can reduce neurological damage and enhance the treatment of conditions such as hypothermia, normothermia, and hyperthermia. This approach enables healthcare professionals to deliver more efficient and effective care to patients in critical situations.
Eyesight & Vision GmbH
Seed Round in 2011
Eyesight & Vision GmbH, founded in 2010 and based in Nürnberg, Germany, specializes in the development and marketing of advanced diagnostic equipment for refractive errors during cataract surgery. The company’s flagship product, the Intraoperative Ocular Wavefront Aberrometer (I-O-W-A), enables surgeons to optimize the selection and positioning of intraocular lenses (IOLs) with enhanced predictability of refractive outcomes and improved patient satisfaction. Utilizing patented "flying spot" technology, the system provides real-time measurements of refractive power and incorporates binocular input reflection through a 3D Head-Up Display, ensuring seamless integration with existing surgical microscopes. This innovative approach facilitates efficient and accurate measurements during surgery, ultimately contributing to better surgical results.
GME German Medical Engineering
Venture Round in 2011
GME German Medical Engineering GmbH, established in 2011 and headquartered in Erlangen, Germany, specializes in the development and marketing of advanced laser and light systems for dermatological applications. The company’s flagship product, the Linscan 808, is a versatile diode laser designed for permanent hair removal, skin tightening, and the treatment of skin conditions such as psoriasis and vitiligo. GME's systems are notable for their ease of use, featuring Plug & Play installation, intelligent software, and WiFi update capabilities. Their compact design facilitates transport, making them suitable for various clinical environments. All products are developed and manufactured in Germany, adhering to stringent medical device approval standards. GME markets its products globally through a network of partner companies, providing innovative solutions to dermatologists in both aesthetic and medical fields.
Heppe Medical Chitosan
Series B in 2010
Heppe Medical Chitosan GmbH, based in Halle, Germany, specializes in the development, production, and sale of biopolymers derived from chitin and chitosan for the cosmetic and pharmaceutical industries. Founded in 2005, the company produces pure chitin and chitosan, along with their derivatives and nanoparticulate forms, adhering to Good Manufacturing Practice (GMP) standards. These biodegradable and non-toxic biopolymers possess unique properties, such as bacteriostatic effects and the ability to bond with proteins and heavy metals. Heppe Medical Chitosan's products are utilized in applications including wound dressing, drug delivery, and tissue engineering, allowing for innovative solutions in healthcare and beauty.
Curefab
Venture Round in 2010
Curefab is a developer of medical technologies focused on enhancing the assessment of diagnostic image data. The company's innovative solutions aim to improve diagnostic certainty and facilitate early detection of cardiovascular and oncological diseases. By providing tools for stroke prevention and early diagnosis of vascular conditions, Curefab enables healthcare professionals to monitor cancer therapies effectively. Additionally, the company offers computed sonography systems that allow for the comparison and analysis of ultrasound image data, equipping physicians with relevant diagnostic parameters to make informed decisions.
Scopis
Seed Round in 2010
Scopis is a developer and manufacturer of clinical navigation system for image guided surgery specializing in laser-based measuring and endoscopic augmented reality. Scopis was founded in August 2010 as a joint spin-off of Charité University Clinic Berlin and Fraunhofer IPK. It received an immediate seed round from German incubator High Tech Gründerfonds (HTGF). The MATRIX POLAR navigation system range was brought on the European market in January 2011. Scopis has since focused on improving the utility of navigation for endoscopic procedures. Notably, the Augmented Reality navigation product MATRIX POLAR AR was launched in August 2011.
SurgicEye
Series A in 2010
SurgicEye GmbH, founded in 2008 and headquartered in Munich, Germany, specializes in intra-operative imaging and instrument navigation solutions tailored for surgical procedures. The company offers several innovative products, including the declipse SPECT open surgery, a navigated radio-guided surgery system utilizing handheld 3-D freehand SPECT imaging technology; the declipse SPECT Laparascopy, an intraoperative 3D imaging system for performing invasive sentinel lymph node biopsies; and the declipse SPECT imaging probe, a mobile high-resolution SPECT imaging solution. Additionally, SurgicEye provides consulting services in medical device development, including requirement engineering, software specification, software development, and testing for medical devices, as well as support for designing and conducting clinical studies.
Eyetronic Therapie
Series B in 2010
EBS Technologies is a medical device company that has developed a stimulation system for the treatment of neurologically caused impairments such as visual field loss. Such impairments can be the result of stroke, traumatic-brain-injury, glaucoma or several other diseases. The EBS Therapy (previously: NEXT WAVE™Therapy) is a non-invasive optic nerve stimulation deploying weak electrical currents, resulting in neuroregeneration and neuroprotection. Low-voltage electrical pulses are administered at frequencies and amplitudes identified as optimal for each patient, allowing retinal ganglion cells to regenerate and branch out new axons. The company benefits from more than 15 years of research and clinical experience with more than 1,200 patients. Double blind, randomized studies, as well as clinical observations show that the EBS Therapy can partially restore vision field in patients. In 2013 EBS Technologies received the CE Mark for the stimulation device and started the commercial treatment in 2014. There are currently 8 EBS Treatment centers across Germany and the company is slowly widening the network.
PluriSelect
Venture Round in 2009
pluriSelect is a developer of biotechnical devices and supplies designed to offer efficient tools for cell and protein separation. The company's biotechnical devices and supplies help in isolating cells from whole blood, buffy coat, cell culture and other heterogeneous biological liquids and isolate targets from unbound material, enabling researchers in academic science to ensure high quality results and additionally reduce time and resources for their routine tasks.
Eyetronic Therapie
Seed Round in 2009
EBS Technologies is a medical device company that has developed a stimulation system for the treatment of neurologically caused impairments such as visual field loss. Such impairments can be the result of stroke, traumatic-brain-injury, glaucoma or several other diseases. The EBS Therapy (previously: NEXT WAVE™Therapy) is a non-invasive optic nerve stimulation deploying weak electrical currents, resulting in neuroregeneration and neuroprotection. Low-voltage electrical pulses are administered at frequencies and amplitudes identified as optimal for each patient, allowing retinal ganglion cells to regenerate and branch out new axons. The company benefits from more than 15 years of research and clinical experience with more than 1,200 patients. Double blind, randomized studies, as well as clinical observations show that the EBS Therapy can partially restore vision field in patients. In 2013 EBS Technologies received the CE Mark for the stimulation device and started the commercial treatment in 2014. There are currently 8 EBS Treatment centers across Germany and the company is slowly widening the network.
SurgicEye
Seed Round in 2008
SurgicEye GmbH, founded in 2008 and headquartered in Munich, Germany, specializes in intra-operative imaging and instrument navigation solutions tailored for surgical procedures. The company offers several innovative products, including the declipse SPECT open surgery, a navigated radio-guided surgery system utilizing handheld 3-D freehand SPECT imaging technology; the declipse SPECT Laparascopy, an intraoperative 3D imaging system for performing invasive sentinel lymph node biopsies; and the declipse SPECT imaging probe, a mobile high-resolution SPECT imaging solution. Additionally, SurgicEye provides consulting services in medical device development, including requirement engineering, software specification, software development, and testing for medical devices, as well as support for designing and conducting clinical studies.
Sense Inside
Venture Round in 2008
Sense Inside develops a unique diagnostic and therapeutic device specifically for bruxism, the condition characterized by involuntary teeth grinding. This innovative device aims to offer long-term solutions for both diagnosis and treatment, addressing the significant physiological strain experienced by an increasing number of patients. By equipping healthcare professionals with a comprehensive tool, Sense Inside enhances the ability to diagnose and manage dental diseases associated with bruxism.
Heppe Medical Chitosan
Seed Round in 2008
Heppe Medical Chitosan GmbH, based in Halle, Germany, specializes in the development, production, and sale of biopolymers derived from chitin and chitosan for the cosmetic and pharmaceutical industries. Founded in 2005, the company produces pure chitin and chitosan, along with their derivatives and nanoparticulate forms, adhering to Good Manufacturing Practice (GMP) standards. These biodegradable and non-toxic biopolymers possess unique properties, such as bacteriostatic effects and the ability to bond with proteins and heavy metals. Heppe Medical Chitosan's products are utilized in applications including wound dressing, drug delivery, and tissue engineering, allowing for innovative solutions in healthcare and beauty.
MEDOVENT
Seed Round in 2006
MEDOVENT GmbH was founded in summer 2006 by Dr. Thomas Freier and Dr. Rivelino Montenegro. Both have a long-term expertise in the field of biomaterial research and medical device development.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.